Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

BIZARRE: Bicycle therapeutics s return on capital employed overview 1e418455 ee1d 4671 bcf7 054500677798 - What They Never Told You

Benzinga Pro data, Bicycle Therapeutics (NASDAQ:BCYC) reported Q1 sales of $3.86 million. Earnings fell to a loss of $27.56 million, resulting in a 52.82% decrease from last quarter. Bicycle Therapeutics collected $3.77 million in revenue during Q4, but reported earnings showed a $18.04 million loss.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.